Physician profile

Carol Clare

Obstetrics & Gynecology (Nurse Practitioner) · Huntington Station, NY

NPI 1316058654

$462.74

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$79.74

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Exeltis, USA INC. $169.10 2021-2023 Slynd
Abbvie INC. $117.65 2021-2023
Urovant Sciences INC $45.21 2021-2022
Pfizer INC. $28.94 2021
Scynexis, INC. $23.90 2022
Evofem Biosciences, INC. $21.86 2022
Therapeuticsmd, INC. $21.51 2022
Astellas Pharma US INC $18.74 2023 Myrbetriq
Avion Pharmaceuticals $15.83 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Carol Clare

$462.74

in general payments reported 2019-2025

Years
2021-2023
Top company
Exeltis, USA INC.

https://glasscript.com/doctor/11034555/carol-clare

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.